The UBS Global Healthcare Conference is underway in New York this week, and the stocks of several participating companies are on the move.
Here’s a breakdown of which stocks to watch.
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX)
AcelRX announced on Tuesday that is has entered into a contract with the U.S. Department of Defense that is worth up to $17 million. Shares of the $145 million company were up about 8.0 percent following the news.
Affimed NV (NASDAQ: AFMD)
The market liked what it heard out of Affimed’s UBS presentation on Tuesday morning. Shares jumped about 4.0 percent during the talk.
Atara Biotherapeutics (NASDAQ: ATRA)
The market seems to be having the complete opposite reaction to shares of Atara, which have fallen as much as 8.0 percent on Tuesday following the company’s presentation at the UBS conference.
Related Link: BlueBird Bio Soars Off Potential Drug Approval
Cerulean Pharma Inc (NASDAQ: CERU)
Another UBS attendee, Cerulean, is also having a rough day of trading. Shares are down more than 4.2 percent.
Endo International PLC (NASDAQ: ENDP)
Endo shares are popping more than 3.8 percent today after the company announced on Monday that it is buying Par Pharmaceutical Holdings for $8 billion in cash and stock.
Esperion Therapeutics Inc (NASDAQ: ESPR)
Esperion’s stock is breaking out to new 52-week highs in a big way on Tuesday following the company’s UBS presentation on Monday. Esperion’s stock is up 5.5 percent on the day.
Immune Design Corp (NASDAQ: IMDZ)
Immune Design shares are down 3.2 percent ahead of the company’s UBS presentation on Tuesday evening.
See more from Benzinga
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.